You are here
New Drugs/Drug News/New Medical Devices November 2014
NEW DRUG APPROVALS
Harvoni, a Once-Daily, Single-Tablet HCV Regimen
The FDA has approved ledipasvir/sofosbuvir (Harvoni, Gilead Sciences, Inc.), the first once-daily, single-tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults.
Harvoni combines 90 mg of the NS5A inhibitor ledipasvir with 400 mg of the nucleotide analog polymerase inhibitor sofosbuvir (Sovaldi, Gilead). The combination’s efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection with treatment durations of eight, 12, or 24 weeks depending on prior treatment history, cirrhosis status, and baseline viral load. Eight weeks of treatment can be considered for treatment-naïve patients without cirrhosis who have a baseline HCV viral load below 6 million IU/mL.
The approval is supported by data from three phase 3 studies, ION-1, ION-2, and ION-3, that evaluated eight, 12, or 24 weeks of treatment with ledipasvir/sofosbuvir, with or without ribavirin, among nearly 2,000 genotype 1 HCV patients with compensated liver disease. These studies included cirrhotic and noncirrhotic patients who were treatment-naïve or had failed prior therapy with interferon-based regimens, including those containing an HCV protease inhibitor. The primary endpoint for each study was sustained virologic response (undetectable HCV) 12 weeks after completing therapy (SVR12).
Patients who achieve SVR12 are considered cured of HCV. In these studies, ribavirin was not shown to increase response rates. Trial participants in the ribavirin-free arms (n = 863) achieved SVR12 rates of 94% to 99%.
Adverse events led to treatment discontinuation among 1% or less of patients. Fewer adverse events were observed in the ribavirin-free arms compared with the ribavirin-containing arms. The most common adverse reactions with ledipasvir/sofosbuvir (5% or more) were fatigue, headache, nausea, diarrhea, and insomnia.
Source: Gilead Sciences, October 10, 2014
Trulicity for Type-2 Diabetes
The FDA has approved dulaglutide (Trulicity, Eli Lilly and Company), a once-weekly subcutaneous injection to improve glycemic control along with diet and exercise in adults with type-2 diabetes.
The safety and effectiveness of dulaglutide, a glucagon-like peptide-1 receptor agonist, were evaluated in six clinical trials; 3,342 patients with type-2 diabetes received dulaglutide and showed reductions in hemoglobin A1c. Dulaglutide has been studied as monotherapy and in combination with other type-2 diabetes therapies, including metformin, sulfonylurea, thiazolidinedione, and prandial insulin. It should not be used to treat people with type-1 diabetes, diabetic ketoacidosis, or severe gastrointestinal problems, or as first-line therapy for patients who cannot be managed with diet and exercise.
A boxed warning notes that thyroid C-cell tumors have been seen in rodent studies with dulaglutide, but it is not known whether the drug causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Dulaglutide should not be used in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (which predisposes patients to MTC).
The FDA is requiring post-marketing studies to evaluate dulaglutide’s dosing, efficacy, and safety in pediatric patients; assess its potential effects on sexual maturation, reproduction, and central nervous system development and function in immature rats; compare dulaglutide with insulin glargine for glycemic control in patients with type-2 diabetes and moderate or severe renal impairment; and evaluate dulaglutide’s cardiovascular effects on patients with high baseline risk of cardiovascular disease. The FDA is also requiring an MTC case registry for at least 15 years to identify any dulaglutide-related increase in MTC incidence.
The FDA approved Trulicity with a risk evaluation and mitigation strategy. In clinical trials, the most common side effects were nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.
Source: FDA, September 18, 2014
Akynzeo for CINV
Netupitant/palonosetron (Akynzeo, Helsinn Group/Eisai Inc.) has received FDA approval for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including highly emetogenic chemotherapy.
The fixed-combination oral agent targets two critical signaling pathways associated with chemotherapy-induced nausea and vomiting (CINV) by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV. The approval was based on phase 2 and 3 trial data from patients undergoing treatment with moderately and highly emetogenic chemotherapy regimens for a variety of tumors. The most common adverse events included headache, asthenia, fatigue, dyspepsia, constipation, and erythema.
Studies show that patients often receive antiemetic drug regimens that are inconsistent with CINV treatment guidelines, which call for multiple-pathway targeted antiemetic prophylaxis. The combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone meets guideline recommendations for optimal antiemetic therapy following highly emetogenic chemotherapy.
The efficacy of netupitant/palonosetron was established in a pivotal phase 2, randomized, double-blind, dose-ranging study in 694 patients undergoing cisplatin-based chemotherapy for a variety of tumors; 135 chemotherapy-naive patients received netupitant 300 mg/palonosetron 0.5 mg and 136 received oral palonosetron 0.5 mg.
A complete response (CR) was defined as no emetic episode and no use of rescue medication. For all phases—acute (0 to 24 hours), delayed (25 to 120 hours), and overall (0 to 120 hours)—netupitant/palonosetron showed significantly higher CRs compared with oral palonosetron: 98.5% versus 89.7%, 90.4% versus 80.1%, and 89.6% versus 76.5%, respectively.
In a randomized, double-blind, parallel-group, phase 3 study, 1,455 chemotherapy-naive patients were randomly assigned to receive a single oral dose of either netupitant/palonosetron plus dexamethasone or palonosetron plus dexamethasone prior to receiving anthracycline and cyclophosphamide-based chemotherapy. Among patients taking netupitant/palonosetron compared with palonosetron, a CR was seen in 88.4% versus 85.0% in the acute phase, 76.9% versus 69.5% in the delayed phase, and 74.3% versus 66.6% in the overall phase, respectively.
Source: Helsinn Group/Eisai Inc., October 13, 2014
Iluvien for Diabetic Macular Edema
The FDA has approved fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences, Inc.) for the treatment of diabetic macular edema in patients who have previously been treated with corticosteroids and did not have a clinically significant rise in intraocular pressure.
Each fluocinolone acetonide 0.19-mg implant is designed to release submicrogram levels of corticosteroid for 36 months. The approval was based on clinical trial data showing that at month 24 after receiving the implant, 28.7% of patients had an improvement of 15 letters or more from baseline in their best corrected visual acuity on the Early Treatment Diabetic Retinopathy Study eye chart.
Iluvien is injected into the back of the patient’s eye with an applicator that employs a 25-gauge needle, allowing for a self-sealing wound. In a clinical trial, the most frequently reported adverse drug reactions included cataract development and increased ocular pressure.
Source: Alimera Sciences, Inc., September 29, 2014
Movantik for Constipation Related to Opioid Use
Naloxegol (Movantik, AstraZeneca) has received FDA approval as an oral treatment for opioid-induced constipation in adults with chronic noncancer pain.
Opioids often reduce the gastrointestinal tract’s motility, hampering bowel movements. Naloxegol, a peripherally acting opioid receptor antagonist, reduces this effect.
Naloxegol’s safety and effectiveness were established in two clinical trials involving 1,352 participants who had been treated with opioids for at least four weeks for noncancer-related pain and who had opioid-induced constipation. Participants were randomly assigned to receive 12.5 mg or 25 mg of naloxegol or placebo once daily for 12 weeks. Results from the first trial showed an increase in bowel movements per week among 44% of the participants receiving naloxegol 25 mg, 41% of those receiving naloxegol 12.5 mg, and 29% of those given placebo. The second trial reported similar results.
Common side effects of naloxegol include abdominal pain, diarrhea, headache, and flatulence. The FDA is requiring a post-marketing study to evaluate the potential risk of cardiovascular adverse events in patients treated with naloxegol.
Source: FDA, September 16, 2014
Stribild Components for HIV-1
Two of the four components of Stribild, Gilead Sciences’ once-daily treatment for human immunodeficiency virus type 1 (HIV-1), have received FDA approval as separate medications.
Elvitegravir (Vitekta, Gilead Sciences) is an HIV-1 integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor (atazanavir, lopinavir, darunavir, fosamprenavir, or tipranavir) co-administered with ritonavir and another antiretroviral drug for the treatment of HIV-1 infection in anti-retroviral treatment-experienced adults. It is available in 85-mg and 150-mg tablets.
Cobicistat (Tybost, Gilead Sciences) is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (in a once-daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in treatment-naïve or treatment-experienced patients. It is available as 150-mg tablets.
Stribild also contains emtricitabine and tenofovir disoproxil fumarate.
Source: FDA, September 25, 2014
Par Pharmaceutical Companies, Inc., has received FDA approval for all four strengths of amlodipine/valsartan tablets—the first generic versions of Novartis’ hypertension medication Exforge.
Amlodipine/valsartan tablets contain amlodipine besylate equivalent to 5 mg or 10 mg of amlodipine free-base with valsartan 160 mg or 320 mg. The following combinations are available: 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg, and 10 mg/320 mg. According to IMS Health data, annual U.S. sales of Exforge are approximately $422 million.
The product has a boxed warning regarding fetal toxicity.
Source: Par Pharmaceutical Companies, Inc., September 30, 2014
Daptomycin for Injection
Hospira, Inc., has received FDA approval for daptomycin for injection USP, 500 mg, packaged in single-use vials. This is the first generic equivalent of Cubicin for Injection, manufactured by Cubist Pharmaceuticals, Inc. However, Hospira and Cubist are engaged in ongoing patent litigation that will affect availability.
Cubicin is a lipopeptide antibacterial indicated for the treatment of complicated skin and skin structure infections and Staphylococcus aureus bloodstream infections, including those with right-sided infective endocarditis.
Sources: FDA, September 12, 2014, and Cubicin prescribing information
Moxifloxacin Hydrochloride Ophthalmic Solution
The FDA has approved Lupin Limited’s moxifloxacin hydrochloride ophthalmic solution USP, 0.5% (base)—the first generic version of Alcon’s Vigamox ophthalmic solution, a topical fluoroquinolone anti-infective indicated for the treatment of conjunctivitis caused by certain susceptible bacteria.
Sources: FDA, September 4, 2014, and Vigamox prescribing information
Velcade for Untreated MCL
Bortezomib for injection (Velcade, Millenium/Takeda) has become the first medication to receive FDA approval for use in previously untreated patients with mantle cell lymphoma (MCL). Bortezomib was approved in 2006 for use in relapsed or refractory MCL, a rare, aggressive type of B-cell non-Hodgkin lymphoma that usually occurs in older adults.
The approval is based on a randomized, open-label, prospective, head-to-head phase 3 study of 487 patients with previously untreated MCL who were ineligible or not considered for a bone-marrow transplant. Patients who received the so-called VcR-CAP regimen—Velcade, rituximab, cyclophosphamide, doxorubicin, and prednisone—experienced a 59% relative improvement in progression-free survival (PFS) compared with those who received the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen (median PFS, 25 versus 14 months) at a median follow-up of 40 months.
The most common adverse reactions occurring in at least 20% of patients receiving VcR-CAP were neutropenia, leukopenia, anemia, thrombocytopenia, lymphopenia, peripheral neuropathy, pyrexia, nausea, and diarrhea.
Source: Millennium, October 10, 2014
Otezla for Plaque Psoriasis
Apremilast (Otezla, Celgene Corp.) has received FDA approval for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
Apremilast, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), was approved in March 2014 for use in adults with active psoriatic arthritis. It is the first PDE4 inhibitor indicated for the treatment of plaque psoriasis.
The new indication is based primarily on safety and efficacy results from two randomized, double-blind, placebo-controlled studies (ESTEEM 1 and ESTEEM 2) conducted in approximately 1,250 adults who had moderate-to-severe plaque psoriasis for at least 12 months prior to screening and who were candidates for phototherapy, systemic therapy, or both.
Treatment with apremilast resulted in significant and clinically meaningful improvements in Psoriasis Area and Severity Index scores at week 16. Clinical improvement, as measured by static Physician Global Assessment (sPGA) scores of “clear” to “almost clear,” was also demonstrated in both studies.
Adverse events associated with apremilast in clinical trials included diarrhea, nausea, upper respiratory tract infection, tension headache, and headache.
Apremilast specifically targets cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is thought to modulate indirectly the production of inflammatory mediators.
Source: Celgene, September 23, 2014
Eylea for Macular Edema
The FDA has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for the treatment of macular edema following retinal vein occlusion (RVO), which includes macular edema following branch retinal vein occlusion (BRVO) in addition to the previously approved indication of macular edema following central retinal vein occlusion (CRVO).
The recommended dosage for patients with macular edema following RVO is 2 mg every four weeks.
The expanded indication is based on the previously approved indication for macular edema following CRVO and on positive results from the double-masked, randomized, controlled phase 3 VIBRANT study in 181 patients with macular edema following BRVO. VIBRANT compared aflibercept 2 mg once every four weeks with macular laser photocoagulation. At 24 weeks, significantly more patients treated with aflibercept gained at least 15 letters in vision (three lines on an eye chart) from baseline compared with patients who received laser photocoagulation (53% versus 27%, respectively).
The incidence of nonocular serious adverse events (AEs) was 8.8% in the aflibercept group compared with 9.8% in the laser photocoagulation group. The most common ocular AEs in patients using aflibercept included conjunctival hemorrhage and cataract.
Aflibercept, a vascular endothelial growth factor inhibitor, recently received FDA breakthrough therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two phase 3 trials (VIVID-DME and VISTA-DME).
Source: Regeneron Pharmaceuticals, Inc., September 16, 2014, and October 6, 2014
Relistor for Constipation Induced by Opioid Use
The FDA has approved methylnaltrexone bromide (Relistor, Salix Pharmaceuticals) subcutaneous injection, 12 mg/0.6 mL, for the treatment of opioid-induced constipation (OIC) in patients receiving opioids for chronic noncancer pain. It is the only peripherally acting mu-opioid receptor antagonist approved for treating OIC at the cause without interfering with the centrally acting analgesic properties of the opioid.
In a randomized, double-blind, placebo-controlled trial, 312 patients with noncancer pain and OIC who had been taking opioids for at least a month received methylnaltrexone bromide 12 mg or placebo once daily for four weeks, followed by an eight-week open-label phase during which patients could take medications as needed. More patients treated with methylnaltrexone bromide reported having three or more spontaneous bowel movements per week during the four-week double-blind period compared with placebo (59% versus 38%, respectively).
Source: Salix Pharmaceuticals, September 29, 2014
Rixubis for Hemophilia B Among Children
The FDA has approved coagulation factor IX, recombinant (Rixubis, Baxter International Inc.) for routine prophylactic treatment, control, and prevention of bleeding episodes and for perioperative management in children with hemophilia B.
Rixubis was the first recombinant factor IX to be approved for routine prophylaxis and control of bleeding episodes in the U.S. for adults with this condition. The new approval was based on the results of a clinical trial investigating the efficacy and safety of Rixubis in 23 previously treated boys younger than 12 years of age with severe or moderately severe hemophilia B. The patients were treated with a twice-weekly Rixubis prophylaxis regimen (mean dose: 56 IU/kg) for a mean period of six months and a mean of 54 exposure days.
The median annualized bleeding rate was 2.0 (0.0 for spontaneous bleeds and joint bleeds). Nine patients (39%) experienced no bleeds, and 23 bleeding episodes (89%) were treated with one or two infusions. There were no reports of inhibitor development, severe allergic reactions, or thrombotic or treatment-related adverse events (AEs). The most common AEs in clinical studies included dysgeusia, pain in an extremity, and a positive test for furin antibody.
Source: Baxter International Inc., September 15, 2014
Humira for Pediatric Crohn’s Disease …
The FDA has approved an eighth indication for adalimumab (Humira, AbbVie)—for reducing signs and symptoms of Crohn’s disease and achieving and maintaining clinical remission among pediatric patients 6 years of age and older who have had an inadequate response to corticosteroids or to immunomodulators. Adalimumab is the first biologic approved for use in this patient population that can be administered at home.
The FDA’s decision was supported by the phase 3, randomized, double-blind IMAgINE-1 trial, which evaluated multiple dosing strategies for adalimumab to induce and maintain clinical remission in patients 6 to 17 years of age with moderately to severely active Crohn’s disease (CD) for whom certain other treatments had not worked well.
Adalimumab works by inhibiting tumor necrosis factor alpha. It can be self-administered by patients with proper training and appropriate physician monitoring.
Source: AbbVie, September 25, 2014
… And for Younger JIA Patients
The FDA has extended the indication for adalimumab (Humira, AbbVie) for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to include reducing signs and symptoms in patients 2 years of age and older. Adalimumab was approved in the U.S. in 2008 for polyarticular JIA in patients 4 years of age and older.
Source: AbbVie, October 6, 2014
Stendra Acts Quickly For Erectile Dysfunction
Avanafil (Stendra, Vivus, Inc./Auxilium Pharmaceuticals) has become the only FDA-approved erectile dysfunction medication indicated for use just 15 minutes before sexual activity. The FDA approved new labeling for avanafil under a supplemental new drug application (sNDA).
Avanafil is a phosphodiesterase 5 (PDE5) inhibitor approved for the treatment of erectile dysfunction (ED) in men 18 years of age or older.
In a study that assessed the efficacy of two dosage strengths, 440 men treated with avanafil had a significantly higher proportion of attempts that enabled an erection sufficient for successful sexual intercourse as early as approximately 15 minutes following administration compared with placebo. The previously approved prescribing information recommended administration approximately 30 minutes before sexual activity.
Source: Auxilium Pharmaceuticals, September 18, 2014
Spiriva Respimat for COPD
Tiotropium bromide inhalation spray (Spiriva Respimat, Boehringer Ingelheim) has received FDA approval for long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and to reduce exacerbations in COPD patients.
Spiriva Respimat provides a premeasured amount of medicine in a slow-moving mist that helps patients inhale the medicine. It was developed to deliver medication in a way that does not rely on how fast air is breathed in from the inhaler.
Spiriva Respimat has the same active ingredient as Spiriva HandiHaler (tiotropium bromide inhalation powder), which will remain available. Its approval was based on data from seven clinical trials in which 8,700 patients were treated with Spiriva Respimat. The most common side effects included sore throat, cough, dry mouth, and sinus infection.
Source: Boehringer Ingelheim, September 25, 2014
Breakthrough Status for AP26113 In Some Lung Cancer Patients
AP26113 (Ariad Pharmaceuticals) has received an FDA breakthrough therapy designation for patients with anaplastic lymphoma kinase positive (ALK+) metastatic non–small-cell lung cancer (NSCLC) who are resistant to crizotinib (Xalkori, Pfizer).
This designation was based on results from an ongoing phase 1/2 trial that showed sustained antitumor activity of AP26113 in patients with ALK+ NSCLC, including patients with active brain metastases. Of the 72 ALK+ NSCLC patients evaluable for response, 52 (72%) demonstrated an objective response. The median duration of response was 49 weeks, and the median progression-free survival was 56 weeks. Responses were seen in patients who were either tyrosine kinase inhibitor–naïve or resistant to crizotinib.
The most common adverse events were nausea, diarrhea, and fatigue.
AP26113 was designed to overcome mutation-based resistance that has been observed in patients who initially responded to crizotinib and then relapsed.
Source: Ariad Pharmaceuticals, October 2, 2014
Priority Review Status
Palbociclib for Breast Cancer
Palbociclib (Pfizer) has received the FDA’s priority review designation as a first-line treatment, in combination with letrozole, for postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer who have not received previous systemic treatment for the disease.
Pfizer’s submission of a new drug application was based on results from the randomized, phase 2 PALOMA-1 trial, which compared palbociclib plus letrozole with letrozole alone in postmenopausal women with ER+, HER– advanced breast cancer. The Prescription Drug User Fee Act goal for an FDA decision is April 13, 2015.
Palbociclib is an investigational oral, targeted agent that selectively inhibits cyclin-dependent kinases 4 and 6 to regain cell-cycle control and to block tumor cell proliferation. It received a breakthrough therapy designation from the FDA in April 2013 for the first-line systemic treatment of women with advanced or metastatic ER+, HER2– breast cancer.
Source: Pfizer, October 13, 2014
Vyvanse for Eating Disorders
The FDA has given a priority review designation to a supplemental new drug application for lisdexamfetamine dimesylate (Vyvanse, Shire PLC) as a treatment for adults with binge eating disorder (BED). A decision is expected in February 2015.
Lisdexamfetamine, approved for the treatment of attention-deficit/hyperactivity disorder in the U.S., is a Schedule II controlled substance. Regulatory approval is being sought for lisdexamfetamine as a BED treatment option based on the results of two randomized, placebo-controlled phase 3 studies that evaluated the efficacy and safety of lisdexamfetamine compared with placebo.
In both studies, lisdexamfetamine was found to be statistically superior to placebo on the primary efficacy analysis of the change from baseline at weeks 11 to 12 in the number of binge days per week.
Source: Shire PLC, September 15, 2014, and November 5, 2013
Orphan Drug Designations
A neuroblastoma vaccine being developed by MabVax Therapeutics Holdings, Inc., has received FDA orphan drug designation. MabVax expects to start a phase 2 clinical trial in 2015 for the bivalent vaccine, which elicits an antibody response targeting the two most common antigens on neuroblastoma cells in an effort to kill residual cancer cells that can cause recurrence.
About 650 to 800 cases of the rare extra-cranial solid tumor cancer are diagnosed annually in North America; approximately 90% of patients are younger than 5 years of age.
A phase 1 trial at Memorial Sloan-Kettering Cancer Center reported encouraging results in a small cohort of difficult-to-treat patients who had repeatedly relapsed prior to use of the vaccine. The vaccine is intended for patients with relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment.
Source: MabVax Therapeutics Holdings, Inc., September 25, 2014
PEGPH20 for Pancreatic Cancer
Halozyme Therapeutics, Inc., has received an FDA orphan drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Halozyme is investigating PEGPH20 in a phase 2 study in combination with gemcitabine and nabpaclitaxel in metastatic pancreatic cancer.
Source: Halozyme Therapeutics, Inc., October 3, 2014
DNX-2401 for Malignant Glioma
The FDA has granted orphan drug designation for DNX-2401 (DNAtrix, Inc.), a conditionally replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer. The DNX-2401 program has already been granted fast-track status, and DNX-2401 is being evaluated in clinical studies in the U.S. and Europe.
Source: DNAtrix, Inc., October 7, 2014
SYN-005 for Pertussis
The FDA has awarded orphan drug designation to SYN-005 (Synthetic Biologics, Inc.), a monoclonal antibody combination for the treatment of pertussis. Synthetic Biologics is developing SYN-005 in collaboration with Intrexon Corporation and researchers at the University of Texas at Austin.
Source: Synthetic Biologics, Inc., September 12, 2014
NurOwn for ALS
BrainStorm Cell Therapeutics Inc. has received the FDA’s fast-track designation for NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). NurOwn consists of autologous mesenchymal stem cells that have been induced to secrete neurotrophic factors. NurOwn has been administered to more than 30 patients with ALS in clinical trials in Israel and is being studied in a randomized, double-blind, placebo-controlled trial in the United States.
Source: BrainStorm Cell Therapeutics Inc., October 7, 2014
NKTT120 for Sickle Cell Disease
The FDA has granted fast-track designation to NKTT120 (NKT Therapeutics), a humanized monoclonal antibody being developed to treat sickle cell disease.
NKTT120 specifically depletes iNKT cells, a regulatory T cell shown to be a key mediator of organ damage in preclinical models of sickle cell disease. Treatment with NKTT120 (which has also received an FDA orphan drug designation) reduces iNKT cell-mediated inflammation. NKT Therapeutics has completed dosing in a phase 1b trial of NKTT120 in patients with sickle cell disease.
Source: NKT Therapeutics, October 2, 2014
New Xolair Labeling Cites Heart and Brain Risks
An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain in patients being treated with omalizumab (Xolair, Genentech/Novartis) than in patients who were not treated with this asthma drug. The agency has added information about these potential risks to the “adverse reactions” section of the Xolair label.
The FDA’s review of a five-year safety study found a slightly higher rate of heart and brain blood-vessel problems in patients who were treated with omalizumab than in those who were not. The problems included transient ischemic attacks, heart attacks, sudden chest pain, pulmonary hypertension, and blood clots in the lungs and veins. Because of weaknesses in the study’s design and execution, the FDA was unable to determine the exact increased level of risks.
The agency also reviewed an analysis of 25 randomized, double-blind clinical trials comparing omalizumab with placebo. No increased risk of heart- and brain-related problems in patients treated with omalizumab was noted in this analysis, but the low number of events, the young patient population, and the short duration of follow-up precluded definitive conclusions.
Previous clinical trials have shown slightly higher cancer rates in patients treated with omalizumab compared with those not treated with omalizumab. The FDA’s review of the five-year safety study found no difference in cancer rates between patients who were and were not treated with omalizumab. However, limitations in this study prevented the agency from ruling out a potential risk of cancer with omalizumab, so it has added that information to the “warnings and precautions” section of the drug label.
Source: FDA, September 26, 2014
USPSTF Recommends Aspirin To Prevent Preeclampsia
The U.S. Preventive Services Task Force is supporting the use of low-dose aspirin (81 mg/day) after 12 weeks of pregnancy to prevent preeclampsia and its related health problems in women who are at high risk for the condition, do not show signs or symptoms of it, and can safely take aspirin.
Preeclampsia—characterized by a rise in blood pressure and by excess protein in the urine after 20 weeks of pregnancy—is a leading cause of health complications for expectant mothers and their babies.
For women at high risk, low-dose aspirin has been found to reduce the risk for preeclampsia by 24%, the risk for premature birth by 14%, and the risk for intrauterine growth restriction by 20%. Before taking aspirin, pregnant women should talk with their health care providers to determine their risk level and discuss whether taking aspirin is right for them.
The task force recommendation was published online in the Annals of Internal Medicine and on the group’s website.
Source: USPSTF, September 9, 2014
USPSTF Guidelines for STIs
The U.S. Preventive Services Task Force (USPSTF) has published three final recommendations on the prevention and detection of sexually transmitted infections (STIs).
The USPSTF recommended intensive behavioral counseling for all sexually active adolescents and for adults at increased risk for STIs. Successful counseling approaches include providing basic information about the infections and their transmission, assessing individual risk, providing education regarding condom use, and providing strategies for communicating with partners about safe sex.
Screening for chlamydia and gonorrhea (the most commonly reported STIs) is recommended for sexually active women ages 24 years and younger and for older women who are at increased risk for infection. Women ages 24 years and younger have the highest rates of chlamydia and gonorrhea infection.
For men, the task force concluded, there is not enough evidence to determine the effectiveness of screening for chlamydia and gonorrhea. Unlike women, men with these infections are more likely to experience symptoms for which they would seek medical attention. This can lead to earlier detection and treatment that makes men with these STIs less likely than women to develop long-term complications.
The recommendations appear online in the Annals of Internal Medicine and on the group’s website.
Source: USPSTF, September 23, 2014
Lilly to Drop Lupus Drug
Eli Lilly and Company will discontinue development of tabalumab for the treatment of systemic lupus erythematosus (SLE) after two pivotal phase 3 trials revealed insufficient efficacy.
In the ILLUMINATE 1 study, tabalumab did not achieve the primary endpoint, at either dose studied, of statistically significant improvement on the SLE Responder Index-5, a measurement of lupus disease activity and response, compared to standard of care therapy. In ILLUMINATE 2, the higher dose of tabalumab met this endpoint. However, the collective data from these studies did not meet expectations for efficacy in the context of existing treatments.
Source: Eli Lilly and Company, October 2, 2014
Ketorolac Tromethamine Injection
Sagent Pharmaceuticals, Inc., has recalled three lots of ketorolac tromethamine injection, USP, 30 mg/mL single-dose vials manufactured by Cadila Healthcare Ltd. and distributed by Sagent because the labels provide an incorrect expiration date. Lots MP5021, MP5024, and MP5025 were distributed from September 17, 2014, through October 1, 2014. Questions about returns should be directed to the customer call center at 1-866-625-1618, Monday through Friday, 8 a.m. to 7 p.m. Central time.
Source: Sagent Pharmaceuticals, Inc., October 3, 2014
One Lot of Hospira Heparin Sodium
Hospira, Inc., recalled one lot of heparin sodium, 1,000 USP heparin units/500 mL (2 USP heparin units/mL), in 0.9% sodium chloride injection, 500 mL, because human hair was found sealed between the tube and the film at the round seal of the unused administrative port on the nonprint side of a single container. Lot 41-046-JT (expiring November 1, 2015) was distributed from June 2014 to August 2014. The product is used as an anticoagulant to maintain catheter patency. For assistance, call Stericycle at 1-855-201-4337, Monday through Friday, 8 a.m. to 5 p.m. Eastern time.
Source: Hospira, September 12, 2014
One Lot of Hospira Vancomycin HCl
Hospira, Inc., is recalling one lot of vancomycin hydrochloride for injection, USP, equivalent to 1 g vancomycin (sterile powder), because the product may have experienced temperature variations during shipment. Lot 35-315-DD has an expiration date of November 1, 2015. For assistance, call Stericycle at 1-844-861-6215 between 8 a.m. and 5 p.m. Eastern time, Monday through Friday.
Source: Hospira, Inc., October 7, 2014
New Vaccine Could Prevent 90% of Cervical Cancer
Effective vaccination programs with a new nine-valent human papillomavirus (HPV) vaccine could prevent approximately 90% of invasive cervical cancer cases worldwide, according to a study published in Cancer Epidemiology, Biomarkers, and Prevention. To achieve that potential, however, the vaccine would have to be used more extensively than those already in production.
The investigational nine-valent HPV vaccine provides high-efficacy protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Approximately 85% or more of precancerous lesions of the cervix are attributed to these HPV types.
Researchers based their estimates on data from 12,514 women, ages 15 to 45 years, enrolled in the placebo arms of three clinical trials testing a quadrivalent HPV vaccine. The researchers estimated the number of precancers harboring the HPV types included in the nine-valent vaccine being developed by Merck and currently under review at the FDA.
Source: American Association for Cancer Research, October 1, 2014
Benzodiazepines Linked With Dementia …
Guidelines advise only short-term benzodiazepine use in elderly patients, but long-term treatment remains common—even though extended treatment for insomnia and anxiety has not been proven effective and may be harmful.
Long-term benzodiazepines impair memory and cognition; however, the effects on dementia are less clear, say researchers from the University of Montreal and the University of Bordeaux. Benzodiazepines are given for symptoms (anxiety, insomnia, depression) that increase before dementia is diagnosed. Could benzodiazepines cause those prodromes?
The study assessed benzodiazepine treatments initiated more than five years before a dementia diagnosis using an administrative claims database. The researchers matched 1,796 patients with 7,184 controls and followed them for at least six years.
The risk of Alzheimer’s disease, the study showed, increased by 43% to 51% among people who had used benzodiazepines in the past: 894 people (49.8%) with Alzheimer’s disease had used benzodiazepines, compared with 2,873 controls (40%). At the time of diagnosis, 64.8% of patients and 60.6% of controls were still taking benzodiazepines. Short-term use did not differ between the two groups, but long-term use was markedly more common among Alzheimer’s patients: 32.9% versus 21.8%.
Risk of Alzheimer’s increased when long-acting benzodiazepines were used. Adjusting for potential prodromes for dementia, such as depression, anxiety, and sleep disorders, did not meaningfully alter the results.
While concerned that the drugs are used for too long, in the wrong patients, the researchers nonetheless call benzodiazepines “indisputably valuable tools for managing anxiety disorders and transient insomnia.” They urge focusing on the duration of benzodiazepine use.
Source: BMJ, September 9, 2014
… And With Higher Mortality Than Propofol in ICUs
Continuous-infusion benzodiazepines are linked to an increased likelihood of death in patients who receive mechanical ventilation compared with the sedative propofol, according to a study in the American Journal of Respiratory Critical Care Medicine.
Sedation is often required for ventilated patients in intensive care units (ICUs) to reduce anxiety, provide comfort, and assist in respiratory support. Benzodiazepines, including lorazepam and midazolam, were once considered the standard of care.
University of Utah researchers analyzed data from 13,692 mechanically ventilated patients at 104 U.S. hospitals from 2003 to 2009. ICU mortality was 19.7% in propofol-treated patients compared with 28.8% in midazolam-treated patients, and 19.3% in propofol-treated patients compared with 25.2% in lorazepam-treated patients. Those treated with benzodiazepines spent more time on ventilation and in the ICU.
Patients with renal failure and liver dysfunction have trouble clearing benzodiazepines and are more likely to be oversedated. Patients who stay on a ventilator longer are at higher risk for developing ventilator-associated pneumonia and other complications that come from being sedated for long periods.
Earlier, smaller studies linking benzodiazepines with adverse outcomes triggered a drop in the use of benzodiazepines during the last 10 years. Nevertheless, benzodiazepines remain the sedatives of choice in some U.S. hospitals—largely because these drugs are generic and cost less than other sedatives.
Source: University of Utah, September 30, 2014
Pricier Drugs, Fewer Patients?
The median price of the top 100 drugs rose seven-fold from $1,260 in 2010 to $9,400 in 2014, according to market analyst Evaluate. Meanwhile, the median patient population size served by a top-100 drug fell by more than three-quarters, from 690,000 in 2010 to 146,000 in 2014.
The number of treatments costing in excess of $100,000 per patient per year rose to seven in 2014 versus four in 2010.
The Evaluate report describes a fundamental shift to high-priced medicines treating smaller patient population sizes, causing friction between payers and companies. Still, the firm expects the costly drugs to get an increasing slice of the U.S. market as payers drop poorly differentiated products. The report was derived from the company’s new EvaluatePharma USA Sales, Volume, and Pricing Analysis.
Source: Evaluate Ltd., September 25, 2014
Probiotics May Reduce Radiation-Caused Diarrhea
Probiotics may help ease a common side effect of pelvic cancer radiation therapy—diarrhea—but the benefits might not show up right away. According to researchers from Hôtel Dieu de Québec, probiotics were most effective in the weeks after radiation treatment.
No prophylactic agents are approved for preventing pelvic radiation enteritis, the researchers note, and evidence is weak for nutritional interventions. But more research is pointing to a role for probiotics in various gastrointestinal uses.
In the study, 229 patients undergoing radiotherapy received placebo or one of two regimens using the probiotic Bifilact: a standard dose twice a day, or a high dose three times a day. Patients recorded their digestive symptoms every day and met with a registered dietitian and radiation oncologist every week.
Although the differences were not statistically significant, probiotics eventually halved the proportion of patients with moderate-to-severe diarrhea. After 60 days, 35% of patients in the standard-dose Bifilact group did not have moderate-to-severe diarrhea, compared with 17% in the placebo group. For patients who underwent surgery before radiation, probiotic intake tended to reduce all levels of diarrhea, especially grade 4.
The researchers say six clinical studies have shown positive results for probiotics on diarrhea toxicity, frequency of bowel movement, and/or stool consistency during radiation treatment. The benefits of probiotics may be delayed because of the time required by bacteria to exert their influence on the inflammatory process, the researchers add.
Source: Clinical Nutrition, October 2014
771 Cancer Therapies in Pipeline
American biopharmaceutical research companies have 771 medicines and vaccines for cancer in clinical trials or awaiting FDA review, according to a report by the Pharmaceutical Research and Manufacturers of America. The list includes 98 for lung cancer, 87 for leukemia, 78 for lymphoma, 73 for breast cancer, 56 for skin cancer, and 48 for ovarian cancer.
Source: Pharmaceutical Research and Manufacturers of America, October 6, 2014
FDA Seeks Better Cybersecurity
Manufacturers should consider cybersecurity risks as they design and develop medical devices, the FDA says. Companies should submit documentation to the FDA about the risks they identify and the steps they’ve taken to mitigate them.
The recommendations are part of final guidance the FDA has given manufacturers for managing medical-device cybersecurity risks to better protect patient health and information. The guidance also recommends that manufacturers provide the FDA with plans for providing patches and updates to operating systems and medical software.
FDA concerns about cybersecurity vulnerabilities include malware infections on network-connected devices or computers, smartphones, and tablets used to access patient data; unsecured or uncontrolled distribution of passwords; failure to provide timely security software updates and patches to medical devices and networks; and security vulnerabilities in off-the-shelf software designed to prevent unauthorized access to the device or network.
The FDA has no indications that specific devices or systems have been purposely targeted and no reports that patients have been harmed as a result of cybersecurity breaches.
Source: FDA, October 1, 2014
Glucose Monitoring System
The FDA has approved a new indication for the Nova StatStrip Glucose Hospital Meter System (Nova Biomedical), extending its use to critically ill patients—making it the first blood glucose monitoring system (BGMS) specifically indicated for use in all types of hospital patients.
BGMSs, also called blood glucose meters, are handheld devices that analyze the glucose level in a drop of blood on a test strip. The FDA determined that the Nova StatStrip Glucose Hospital Meter System is simple to use and has a low risk of false results.
The FDA gave the device a “clearance waived” test system status under the Clinical Laboratory Improvement Amendments (CLIA). This will allow a variety of health care professionals to perform the test at the point of care, such as a patient’s bedside, instead of requiring that the test be performed in a lab that meets CLIA requirements for high-complexity testing.
Data supporting this clearance included a study of more than 1,650 patients with a range of medical conditions. The results showed agreement in blood glucose results compared with a laboratory glucose analyzer in all patient types tested.
Source: FDA, September 24, 2014
EnVe and ReVel ventilators
EnVe and ReVel ventilators (CareFusion 203, Inc.) are being recalled because potential damage to power-cord adaptors could cause them to shut down.
The ventilators can operate on battery or external power. However, the pins of the external power connector do not always align properly with the input port of the ventilator. Misalignment can damage these pins and possibly short-circuit the ventilator. A short-circuit in the power supply may prevent the ventilator battery from recharging, and the ventilator could lose power unexpectedly. The company has received 256 reports of incidents, with no injuries or deaths.
The units were distributed from December 10, 2010, until August 6, 2014. Call the CareFusion Recall Center with questions about the Class I recall at 1-888-562-6018, Monday through Friday, 7 a.m. to 4 p.m. Pacific time.
Source: FDA, October 9, 2014
Hudson RCI Pediatric Anesthesia Breathing Circuits
Teleflex Medical is recalling its Hudson RCI Pediatric Anesthesia Breathing Circuits (which deliver anesthesia and other gases from a mechanical ventilator to a hospital patient) because the ends of the devices may crack or break, causing serious and potentially fatal health risks.
About 27,000 devices were distributed worldwide from June 2013 to May 2014. A list of product codes and lot numbers is available at
Source: FDA, October 7, 2014
ConMed Stat2 Flow Controller
ICU Medical, Inc., is recalling ConMed Stat2 Flow Controllers, used in intravenous administration sets, because they were assembled with the wrong internal component. The controller may deliver fluid at a much higher rate than the setting indicates, with potentially serious or fatal consequences.
The Class I recall covers items 011-C9801, 011-C9802, AH7007, B9897, and Z2648. The affected lots, 2768416, 2768417, 2758229, 2785379, 2801951, 34-128-HE, 34-540-Y1, 35-151-SJ, 35-805-JW, 36-137-SL, and 36-469-SL, were distributed from October 2013 to January 2014. Those with questions should contact Customer Service at 1-866-829-9025 (option 8), Monday through Friday, 8:30 a.m. to 4 p.m. Pacific time.
Source: FDA, October 9, 2014
Kunj Gohil, PharmD, RPh
Name: MyLab Gamma
Manufacturer: Esaote, Genoa, Italy
Approval Date: October 3, 2014
Purpose: MyLab Gamma is an ultrasound system that resembles a laptop in its size, lightweight portability, and use of applications. These applications allow the system to be used in a variety of scenarios in clinics and other point-of-care sites.
Description: The system has the capability to record both 3D and 4D images, and with the wide range of probes it can be used by physicians in women’s health, general imaging, and nontraditional point-of-care applications. The advanced clinical technologies can also perform cardiac and vascular exams such as transesophageal echo, strain, stress echo, and other qualitative studies. MyLab Gamma maintains wireless connectivity, remote service capabilities, and quick boot times.
Benefit: Physicians are increasingly pressured to deliver high-quality services at an affordable cost in a timely manner. This easy-to-use system gives providers a new device they can employ in various environments whenever they need.
Manufacturer: T2 Biosystems, Lexington, Massachusetts
Approval Date: September 23, 2014
Purpose: T2Candida is a diagnostic product developed to assist physicians in the timely identification of a Candida infection. The test utilizes a patient’s blood and can look for five clinically relevant species of Candida.
Description: This product uses technologies that break down yeast and release its DNA. Once the DNA is released into the device’s medium, it is rapidly copied and the device will detect the DNA through magnetic resonance technology. If DNA from yeast is found, the T2Candida device will identify the species category and provide an indication for the testing provider. The product uses patient blood to identify a yeast pathogen in only three to five hours.
Benefit: Candida is the most lethal pathogen involved with bloodstream infections causing sepsis. Whereas traditional tests may take up to six days, T2Candida provides physicians a simple way to quickly identify Candida infections within hours. Patient mortality can be dramatically decreased if treatment is initiated within 12 hours upon presentation of symptoms. This test may reduce duration of hospitalization and, in turn, decrease the cost of hospital stays for patients receiving intensive care.
Name: eCareCoordinator and eCareCompanion
Manufacturer: Royal Philips, Andover, Massachusetts
Approval Date: October 1, 2014
Purpose: Both the eCareCompanion and eCareCoordinator are clinical applications that focus on chronic-care management. The applications, part of the Philips Transition to Ambulatory Care (eTrAC) program, are designed to aid in the reduction of hospital readmissions and health care costs.
Description: The eCareCompanion is a patient portal used to share patient-specific characteristics collected by a tablet. Information may be obtained from various devices that can be connected to the tablet, such as a scale, blood pressure meter, blood oximeter, and medication dispenser. The companion may also provide patients with specific alerts, such as medication reminders.
The eCareCoordinator is an application that allows health care professionals to access and monitor patient data every day; data can include weight, blood pressure, and other vital signs collected by the patient. This can also be used to administer health questionnaires to patients and as a communication medium between the various members of a patient care team.
Benefit: Digital health care is a rapidly evolving field that will soon play an integral role in patient care. These applications take a dual approach by providing benefits to both the patient and physician and enabling daily monitoring of various patient characteristics. It will be interesting to see the role these applications assume as more physicians embrace digital modes of communication.